Two Biotech Ideas You May Have Missed: William Gregozeski

May 16, 2013 (Investorideas.com Newswire) Adventurous investors have long sought out micro-cap stocks, attracted by the profit potential of starting on the bottom floor and rocketing toward blue sky.

Biotech, Biopharma Stocks to Watch: (BLGX), (OTC: IGXT; TSX: IGX.V), (SNTS)

Point Roberts, WA - April 30, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks announces recent biotech and biopharma stocks (OTC:BLGX), (OTC: IGXT; TSX: IGX.V) and (SNTS) added to the biotech stock directory at Investorideas.com.

Biopharma/ Diagnostic Stocks to Watch; (ASTX), (ERB), (MRIC), (ONVO), (SHPG) Recent Additions

Point Roberts, WA - April 29, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks announces recent biopharma and diagnostic stocks added to the biotech stock directory at Investorideas.com.

TSX and OTC Biotech/ Life Sciences Stocks (TSX.V: SVA), (OTC: APHB), (OTC: BPTH) Added to Investorideas.com Directories

Point Roberts, WA - April 26, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks releases the following recent TSX and OTC additions to the biotech and life sciences stock directory at Investorideas.com.

TSX and ASX Biotech/ Life Sciences Stocks: (ASX: AHZ), (ASX: AVH), (ASX: CIR), (ASX: IVX), (TSX: AMF) Added to Investorideas.com Directories

Point Roberts, WA - April 26, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks releases the following recent TSX and ASX additions to the biotech and life sciences stock directory at Investorideas.com.

7 Big Growth Stories in Biotech: Keith Markey

March 28, 2013 (Investorideas.com Newswire) As a former biotechnology researcher and 25-year Wall Street veteran, Griffin Securities Inc. Analyst and Scientific Director Keith Markey understands how novel, cutting-edge technology can produce extraordinary new products that bring in revenues with double-digit growth potential.

Small Companies Are Hubs of Future Profit in Regenerative Medicine: Gil Van Bokkelen

February 28, 2013 (Investorideas.com Newswire) Gil Van Bokkelen has been in the stem cell industry for more than a decade. In recent years, the co-founder, chairman and chief executive officer of Athersys Inc. has stepped into regenerative medicine's forefront, acting as a spokesman for the industry as well as demonstrating his love of science and passionately advocating for patients.

OTC Biotech/ Pharma Stocks Alert: (OTCBB:SBFM), (OTCQB:ONCS), (OTCQB:XXII), (OTCQB:LJPC)

Point Roberts, WA - January 15, 2013 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert for investors following stocks in the small and microcap markets.

Josh Levine Names Three Biotech Game-Changers

January 3, 2013 (Investorideas.com Newswire) Micro-cap biotechs must have creative, adaptive management first and foremost, says editor Josh Levine of Josh Levine's MicroCap Investor.

Four Biotech Names with Major Market Potential: Michael Higgins

December 20, 2012 (Investorideas.com Newswire) A bit of luck and a lot of capital: Drug companies need both to navigate the seemingly perpetual path leading to the market debut of a new drug.

Zacks Analyst Jason Napodano's Seven Biotech Picks Will Keep Your Profits on Solid Ground

December 13, 2012 (Investorideas.com Newswire) Low valuation in biotech can be like quicksand under a mirage of low-hanging fruit.

Do You Have the Guts to Take On Cutting-Edge Biotech Like This VC?

December 13, 2012 (Investorideas.com Newswire) With the odds stacked against a drug entering clinical trials, investors need to be assured that the upside will be momentous when success does come.

Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes

September 27, 2012 (Investorideas.com Newswire) Once the subject of intense political debate, stem cell therapies may soon be a therapeutic mainstay of healthcare.

Stem Cell Stock Alert; Neuralstem (CUR) Gains over 42%

New York, New York - September 13, 2012 (Investorideas.com Newswire) - Investorideas.com, a leader in sector stock research including biotech stocks, issues a trading alert for stem cell stock Neuralstem, Inc. (NYSE MKT : CUR) , trading at $1.42, up $0.42 or 42.00% as of 11:41AM EDT on over 4 Million shares.

Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico

September 13, 2012 (Investorideas.com Newswire) Biotech has a breeze to its back, and successful progression through the phases of drug development also help propel the industry forward.

Chen Lin's Key to Huge Biotech Profits: Make It Personal

August 23, 2012 (www,investorideas.com newswire) Chen Lin is a well-known expert junior metals and energy investor, but he has found compelling reasons to diversify into biotechnology.

Why M&A Flurry Has Top MKM Analyst Smiling All the Way to the Bank

August 16, 2012 (Investorideas.com newswire) Sometimes bigger is better. In this exclusive interview with The Life Sciences Report, Senior Analyst and Managing Director Dr. Jon LeCroy of MKM Partners points to mergers and acquisitions that have bolstered stock prices and singles out biotech and specialty pharma companies

Think Long Term and Win Big with Small Biotechs: Hugh Cleland

August 9, 2012 (Investorideas.com Newswire) - BluMont Capital Portfolio Manager Hugh Cleland has taken a venture capital and private equity approach to investing in public companies, some of which have penny-stock market caps in the $5-15 million range.

Disruptive Biotechnologies Stir Up Profits: Ray Blanco

August 2, 2012 (Investorideas.com newswire) As coeditor of Technology Profits Confidential and contributor to Breakthrough Technology Alert and Penny Sleuth at Agora Financial, Ray Blanco searches far and wide for breakthrough ideas and disruptive technologies that will change the lives of very sick patients.

Sunshine Biopharma, Inc. (OTCBB: SBFM) - Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

New York, New York - July 30, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics LLC on Sunshine Biopharma Inc. (OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a.

Immunotherapies Attack Cancers and Grow Portfolios: Mara Goldstein

July 27, 2012 (Investorideas.com newswire) Sometimes valuations don't match the fundamentals of a stock, according to Cantor Fitzgerald & Co. Senior Biotechnology Analyst Mara Goldstein

Biotech 'Diamonds-in-the-Rough' Promise Huge Potential Returns: Rahul Jasuja

July 19, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Rahul Jasuja, managing director and senior biotechnology analyst with Noble Financial Capital Markets, doesn't shy away from the smallest micro-cap companies.

Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB: SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)

New York, New York - July 9, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a report on biotech companies targeting aggressive forms of cancer; Roche's (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with its lead compound, Adva-27a.

Follow Venture Capital to Big Gains in Biotech: Peter Johann

July 5, 2012 (Investorideas.com Newswire) Peter Johann is a managing general partner at NGN Capital, a venture capital firm that invests in private and public biotech and medical device companies.

Biopharmaceutical Stock Alert: Onyx Pharmaceuticals (NASDAQ: ONXX) Big Moves on FDA Positive Vote

New York, New York - June 21, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), one of the NASDAQ's top gainers, trading at $62.18, up $17.60 or (39.48%) as of 11:14AM EDT on over 16 Million shares.

Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes

SAN DIEGO - June 19, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office (USPTO) has given the Company a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles."

Osiris (Nasdaq: OSIR) Receives Second Approval for Life-Saving Stem Cell Drug

Orlando, FL - June 14, 2012 (Investorideas.com Newswire) - The Street Beat commentary - Osiris Therapeutics, Inc. (Nasdaq:OSIR), announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the

Pharma Stocks Dominate NASDAQ Top Percentage Gainers: ARNA, DNDN, HZMP, RPTP

New York, New York - June 13, 2012 (InvestorIdeas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert on the top percentage gainers for morning trading June13th.

Read More

Subscribe to InvestorIdeas-Biotech News

George Zavoico Lists 10 Biotech Stocks Poised to Run - March 7, 2013

March 7, 2013 (Investorideas.com Newswire) For the first time in ages, conditions for biotech investment are just right.

Oculus Innovative Sciences, Inc. (NasdaqCM:OCLS) - is a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, oral care, surgical, wound care, animal healthcare and others, and has commercialized products in the United States , Europe, India , China , Mexico , and select Middle East countries. The company's headquarters are in Petaluma , California , with manufacturing operations in the United States and Latin America. www.oculusis.com.

Our biotech stocks directory includes Stem Cell Stocks, Medical Stocks, Life Sciences, Therapeutics and Pharma Stocks . Our Directory includes publicly traded biotech stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.

Preview

3SBio Inc. (NasdaqGS:SSRX) is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is developing expanded autologous cellular therapies for the treatment of severe cardiovascular diseases. The company's proprietary cell manufacturing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy.

ABBOTT LABORATORIES (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Ablynx (Brussels: ABLX.BR) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease. Today, the Company has over 25 projects in the pipeline and there are seven Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 280 people.

See the full biotech stocks directory and login as a member or access as a PDF

• AMEX Biotechnology Index (BTK) The Biotechnology Index is designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. - Click here for current quotes of index components
• Amex Pharmaceutical Index (AMEX: ^DRG) Components - click here
• CBN Stock Index: Canadian Biotech News tracks the stock prices of all publicly listed companies involved in the biotechnology industry in Canada. Our Index however is composed of therapeutic and diagnostics companies whose stock price in the quarter ranges above $1.00. The CBN Index is an average of these prices added to a starting baseline of 100.
• NASDAQ Biotechnology Index includes securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. - click here
• S&P Sector Indices Brochure
• First Trust NYSE Arca Biotech Index (FBT)
• Market Vectors Biotech ETF (BBH) -NYSE MKT- Market Vectors exchange-traded products have been offered since 2006 and span many asset classes, including equities, fixed income (municipal and international bonds) and currency markets. The Market Vectors family currently totals $25.1 billion in assets under management, making it the fifth largest ETP family in the U.S. and eighth largest worldwide
• ProShares UltraShort Nasdaq Biotech (BIS)

Biotech stocks News; A Tale of Two Biotech Companies: Q&A With Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sunshine Biopharma (OTCBB: SBFM) Discussing Lead Cancer Products - July 16, 2012

Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB: SBFM) Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer - July 2, 2012

Q&A Interview with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program - October 24, 2011

Biotech Q&A; BioSante Announces Completion of Enrollment in LibiGel Safety Study - June 7, 2011

Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy - June 28, 2011

• As Biotechnology Stocks Soar, Bubble Talk Percolates - Wall Street Journal (Fri, 26 Apr 2013 13:30:28 GMT)  

  As Biotechnology Stocks Soar, Bubble Talk Percolates Wall Street Journal The NASDAQ index, which includes more than 100 of the most actively traded biotech stocks, is currently valued at roughly 88 times last year's earnings--or 21% higher than its average over the previous three years and roughly six times the S&P 500 ... Biotech's latest rally: exuberance or execution?MarketWatch all 4 news articles »

• Exciting Biotech Stocks Investing Ideas Have Explosive Potential - The Market Oracle (Fri, 03 May 2013 14:41:06 GMT)  

  Exciting Biotech Stocks Investing Ideas Have Explosive Potential The Market Oracle In January 2013, The Life Sciences Report debuted its biotech Watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology stocks. All stocks are affected by catalysts, but nowhere ... and more »

• Amgen's Quarter Sucked, But Keep Buying Biotech Stocks, Analysts Urge - TheStreet.com (Wed, 24 Apr 2013 12:55:23 GMT)  

  Philly.com

  Amgen's Quarter Sucked, But Keep Buying Biotech Stocks, Analysts Urge TheStreet.com The Nasdaq Biotechnology Index (NBI) is up 28% this year, far outpacing the broader market indices. But while many biotech stocks are trading at all-time highs, analysts have been keeping their feet smashed against the accelerator pedal, arguing stocks ... Is Amgen Still a Gem?Barron's all 48 news articles »